Cargando…
5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, mainly associated with work or environmental exposure to asbestos. MPM’s molecular profile is largerly unexplored and effective therapies are still lacking. MPM rarely harbours those somatic genetic lesions...
Autores principales: | Bosio, Matteo, Salvaterra, Elena, Datturi, Francesca, Morbini, Patrizia, Zorzetto, Michele, Inghilleri, Simona, Tomaselli, Stefano, Mangiarotti, Patrizia, Meloni, Federica, Cerveri, Isa, Stella, Giulia Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090903/ https://www.ncbi.nlm.nih.gov/pubmed/30123503 http://dx.doi.org/10.1186/s40248-018-0137-4 |
Ejemplares similares
-
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019) -
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
por: Pignochino, Ymera, et al.
Publicado: (2015) -
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study
por: Saracino, Laura, et al.
Publicado: (2021) -
Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma
por: Vrugt, Bart, et al.
Publicado: (2023) -
Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
por: Stella, Giulia M., et al.
Publicado: (2014)